Provectus Biopharmaceuticals is
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects
PV-10
An Investigational Drug for Cancer
PV-10 for Cutaneous, Recurrent and Metastatic Melanoma
A Phase 2 clinical trial has been successfully completed, and a protocol for a Phase 3 clinical trial has been submitted to the FDA.
PV-10 has Received Orphan Drug Designation from the US FDA for the treatment of metastatic melanoma.
PV-10 for Locally Metastatic Liver Cancer
An expanded Phase I clinical trial is currently underway.
PV-10 has Received Orphan Drug Designation from the US FDA for the treatment of liver cancer.
PV-10 for Recurrent Breast Cancer
A Phase I clinical trial has been completed. In conjunction with Moffitt Cancer Center research, further development is currently being assessed.
A Compassionate Use Program for PV-10 is being conducted as an expanded access study.
The Moffitt Cancer Center is performing a mechanism of action study to examine the systemic immune response induced by intralesional PV-10 injections.
PH-10
An Investigational Drug for Psoriasis and Atopic Dermatitis
PH-10 for Psoriasis
A Phase 2c randomized clinical trial has been successfully completed.
A Phase 2b clinical trial has been successfully completed.
PH-10 for Atopic Dermatitis
A Phase 2 clinical trial has been successfully completed.
PH-10's mechanism of action is currently being examined.
Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov.
IN THE MEDIA
January 7, 2015
Provectus to Be Inaugural Member of the AAPI Global Clinical Trial Network
January 6, 2015
Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study
December 30, 2014
Promising Strategy for Advanced Melanoma: Intralesional Therapies Plus Systemic Immunotherapies
December 19, 2014
Decision-Plus Interviews Provectus CFO and COO Peter Culpepper
December 5, 2014
Oncologists examine efficacy of rose bengal against cancer
December 5, 2014
Study Finds Combined PV-10 And Immune Checkpoint Inhibitors Efficient In Melanoma Treatment
December 4, 2014
Rose Bengal and Co-Inhibitory Blockade Improve Anti-Tumor Immunity, Melanoma Regression
December 2, 2014
PV-10 Data Published; Phase 3 Protocol Published
November 20, 2014
PV-10 and checkpoint inhibitor enhance melanoma regression
November 19, 2014
Combination of PV-10 and checkpoint inhibitor boosts melanoma tumour regression
November 18, 2014
Melanoma shows improved regression with combination of PV-10 and checkpoint inhibitor
November 17, 2014
Provectus Biopharmaceuticals Presents PV-10 Data
November 17, 2014
It may just be do or dye time for cancer biotechs
November 14, 2014
Eye-dye melanoma try: Provectus phase III plan for injectable with FDA
November 12, 2014
Provectus Biopharmaceuticals Issues PV-10 Phase 3 Melanoma Protocol to FDA
November 10, 2014
Oncology News Reports on Melanoma Research Presented at ESMO
November 6, 2014
Webcast: Conference Call November 6, 2014 4:00 PM EDT
November 3, 2014
PV-10 in Metastatic Melanoma: Rapid Responses Led Phase 3
November 3, 2014
Investigational Agent For Metastatic Melanoma Shows Rapid Complete Responses In High Proportion Of Patients In Early Trials
October 30, 2014
A New Cancer Drug Worked In Over 50% Of Patients In A Phase II Trial
more...
PRESS RELEASES
December 23, 2014
Provectus Biopharmaceuticals' Protocol for Phase 2 Study of Mechanism of Action of PH-10 on Immunologic Markers of Psoriasis Now Available Online
December 22, 2014
Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study with Aim to Maximize Speed of Enrollment
December 17, 2014
Provectus Biopharmaceuticals To Sponsor American Association of Physicians of Indian Origin
November 14, 2014
Provectus Biopharmaceuticals Extends Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd
November 13, 2014
Provectus Biopharmaceuticals' Protocol for Phase 3 Study Of PV-10 As Treatment for Melanoma Now Available Online
November 10, 2014
Provectus Biopharmaceuticals PV-10 Data Presented at SITC 29TH Annual Meeting
November 6, 2014
Provectus Biopharmaceuticals, Inc. Reports Third Quarter Results
November 6, 2014
Provectus Biopharmaceuticals Submits PV-10 Phase 3 Melanoma Protocol to FDA
November 6, 2014
Provectus Biopharmaceuticals Announces Abstract Available on Intralesional PV-10 and Co-inhibitory Blockade Data for SITC 29th Annual Meeting
November 6, 2014
Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call Today at 4 PM Eastern Standard Time
October 31, 2014
Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call on Thursday, November 6, 2014
October 28, 2014
Provectus' Intralesional PV-10 Clinical Data Published in the Annals of Surgical Oncology
October 16, 2014
Provectus' Intralesional PV-10 Clinical Data to Be Presented to the 2014 International Congress of the Society for Melanoma Research
October 15, 2014
Provectus' Intralesional PV-10 and Co-Inhibitory Blockade Data to Be Presented at SITC 29th Annual Meeting
October 14, 2014
INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents for Provectus Biopharmaceuticals
October 8, 2014
Provectus' Intralesional PV-10 Clinical Data to Be Presented to the Eurasian Federation of Oncology
October 7, 2014
Provectus' Intralesional PV-10 to Be Presented at the 2014 Beijing International Melanoma Congress
September 29, 2014
Provectus Biopharmaceuticals Data Presented At ESMO 2014 Congress Show Ablative, Bystander Effects Of PV-10
September 24, 2014
Provectus Biopharmaceuticals' PV-10 Clinical Data on Melanoma Now Available for European Society for Medical Oncology 2014 Congress
September 23, 2014
Provectus' Intralesional PV-10 and Co-Inhibitory Blockade Data to Be Presented at SITC 29th Annual Meeting
more...
Copyright (c) 2002-2014 Provectus Biopharmaceuticals, Inc.
All rights reserved.
Artwork designed by Tracy E. Miller.
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects
PV-10
An Investigational Drug for Cancer
PV-10 for Cutaneous, Recurrent and Metastatic Melanoma
A Phase 2 clinical trial has been successfully completed, and a protocol for a Phase 3 clinical trial has been submitted to the FDA.
PV-10 has Received Orphan Drug Designation from the US FDA for the treatment of metastatic melanoma.
PV-10 for Locally Metastatic Liver Cancer
An expanded Phase I clinical trial is currently underway.
PV-10 has Received Orphan Drug Designation from the US FDA for the treatment of liver cancer.
PV-10 for Recurrent Breast Cancer
A Phase I clinical trial has been completed. In conjunction with Moffitt Cancer Center research, further development is currently being assessed.
A Compassionate Use Program for PV-10 is being conducted as an expanded access study.
The Moffitt Cancer Center is performing a mechanism of action study to examine the systemic immune response induced by intralesional PV-10 injections.
PH-10
An Investigational Drug for Psoriasis and Atopic Dermatitis
PH-10 for Psoriasis
A Phase 2c randomized clinical trial has been successfully completed.
A Phase 2b clinical trial has been successfully completed.
PH-10 for Atopic Dermatitis
A Phase 2 clinical trial has been successfully completed.
PH-10's mechanism of action is currently being examined.
Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov.
IN THE MEDIA
January 7, 2015
Provectus to Be Inaugural Member of the AAPI Global Clinical Trial Network
January 6, 2015
Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study
December 30, 2014
Promising Strategy for Advanced Melanoma: Intralesional Therapies Plus Systemic Immunotherapies
December 19, 2014
Decision-Plus Interviews Provectus CFO and COO Peter Culpepper
December 5, 2014
Oncologists examine efficacy of rose bengal against cancer
December 5, 2014
Study Finds Combined PV-10 And Immune Checkpoint Inhibitors Efficient In Melanoma Treatment
December 4, 2014
Rose Bengal and Co-Inhibitory Blockade Improve Anti-Tumor Immunity, Melanoma Regression
December 2, 2014
PV-10 Data Published; Phase 3 Protocol Published
November 20, 2014
PV-10 and checkpoint inhibitor enhance melanoma regression
November 19, 2014
Combination of PV-10 and checkpoint inhibitor boosts melanoma tumour regression
November 18, 2014
Melanoma shows improved regression with combination of PV-10 and checkpoint inhibitor
November 17, 2014
Provectus Biopharmaceuticals Presents PV-10 Data
November 17, 2014
It may just be do or dye time for cancer biotechs
November 14, 2014
Eye-dye melanoma try: Provectus phase III plan for injectable with FDA
November 12, 2014
Provectus Biopharmaceuticals Issues PV-10 Phase 3 Melanoma Protocol to FDA
November 10, 2014
Oncology News Reports on Melanoma Research Presented at ESMO
November 6, 2014
Webcast: Conference Call November 6, 2014 4:00 PM EDT
November 3, 2014
PV-10 in Metastatic Melanoma: Rapid Responses Led Phase 3
November 3, 2014
Investigational Agent For Metastatic Melanoma Shows Rapid Complete Responses In High Proportion Of Patients In Early Trials
October 30, 2014
A New Cancer Drug Worked In Over 50% Of Patients In A Phase II Trial
more...
PRESS RELEASES
December 23, 2014
Provectus Biopharmaceuticals' Protocol for Phase 2 Study of Mechanism of Action of PH-10 on Immunologic Markers of Psoriasis Now Available Online
December 22, 2014
Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study with Aim to Maximize Speed of Enrollment
December 17, 2014
Provectus Biopharmaceuticals To Sponsor American Association of Physicians of Indian Origin
November 14, 2014
Provectus Biopharmaceuticals Extends Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd
November 13, 2014
Provectus Biopharmaceuticals' Protocol for Phase 3 Study Of PV-10 As Treatment for Melanoma Now Available Online
November 10, 2014
Provectus Biopharmaceuticals PV-10 Data Presented at SITC 29TH Annual Meeting
November 6, 2014
Provectus Biopharmaceuticals, Inc. Reports Third Quarter Results
November 6, 2014
Provectus Biopharmaceuticals Submits PV-10 Phase 3 Melanoma Protocol to FDA
November 6, 2014
Provectus Biopharmaceuticals Announces Abstract Available on Intralesional PV-10 and Co-inhibitory Blockade Data for SITC 29th Annual Meeting
November 6, 2014
Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call Today at 4 PM Eastern Standard Time
October 31, 2014
Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call on Thursday, November 6, 2014
October 28, 2014
Provectus' Intralesional PV-10 Clinical Data Published in the Annals of Surgical Oncology
October 16, 2014
Provectus' Intralesional PV-10 Clinical Data to Be Presented to the 2014 International Congress of the Society for Melanoma Research
October 15, 2014
Provectus' Intralesional PV-10 and Co-Inhibitory Blockade Data to Be Presented at SITC 29th Annual Meeting
October 14, 2014
INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents for Provectus Biopharmaceuticals
October 8, 2014
Provectus' Intralesional PV-10 Clinical Data to Be Presented to the Eurasian Federation of Oncology
October 7, 2014
Provectus' Intralesional PV-10 to Be Presented at the 2014 Beijing International Melanoma Congress
September 29, 2014
Provectus Biopharmaceuticals Data Presented At ESMO 2014 Congress Show Ablative, Bystander Effects Of PV-10
September 24, 2014
Provectus Biopharmaceuticals' PV-10 Clinical Data on Melanoma Now Available for European Society for Medical Oncology 2014 Congress
September 23, 2014
Provectus' Intralesional PV-10 and Co-Inhibitory Blockade Data to Be Presented at SITC 29th Annual Meeting
more...
Copyright (c) 2002-2014 Provectus Biopharmaceuticals, Inc.
All rights reserved.
Artwork designed by Tracy E. Miller.
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
